The Mechanism of Beta-Globin Gene Silencing in Embryonic-Fetal Erythroid Cells

胚胎-胎儿红细胞中β-珠蛋白基因沉默的机制

基本信息

项目摘要

The molecular mechanisms which govern the developmental specificity of human beta-globin gene transcription has been studied in K562 cells, a human eyrthroleukemia line that expresses minimal beta-globin. Protein-binding analysis reveals the 5' region contains three elements bound by trans-acting factors, beta-protein 1 (BP1) and beta-protein 2 (BP2). In vitro mutagenesis of each element in a beta-globin vector containing chloramphenicol acetyltransferase (pCAT) followed by transient transfection into K562 cells increased levels of CAT activity 5.5-fold higher than wt beta-CAT, consistent with their silencing role. Mutagenesis of all three elements, however, resulted in activity significantly lower than wt beta-CAT. BP1 and BP2 motifs have overlapping binding sites with high mobility group proteins (HMG1+2), DNA-bending factors shown here by circular permutation assay to extrinsically bend the beta-globin distal promoter. Theoretically, mutations in all beta-protein binding sites could affect the binding of HMG1+2 sufficiently to impede DNA-protein and/or protein-protein interactions needed to facilitate the low level, constitutive gene expression. Placing two helical turns of DNA between BP1 and BP2 motifs also increased expression 3-fold, indicative of spatial constraints required for optimal silencing. However, insertion of the HMG1+2 DNA-bending motif (also equivalent to two turns) facilitates beta-silencing by re-establishment of BP1-BP2 proximity. Thus a combination of general DNA-bending and specific transcriptional factors appear to be involved in beta-globin silencing in the embryonic/fetal erythroid stage. To further define this relationship an in vivo study using transgenic animals is underway. Preparation of a cosmid containing the uLCRbeta locus with a mutated BP1 silencing motif will permit an in vivo analysis of adult beta-globin gene expression in transgenics during the embryonic/fetal developmental stages. We are using two approaches i). PCR site directed mutagenesis and ii). Recombinant-A Restriction endonuclease-cleavage(RARE) method to create of the mutated BP1 binding site with the beta-globin cosmid. The latter technique might also prove useful in testing the hypothesis directly in the context of K562 chromosomal DNA.
控制人类β-珠蛋白基因转录发育特异性的分子机制已经在K562细胞中进行了研究,K562细胞是一种表达最低β-珠蛋白的人红细胞白血病株。蛋白质结合分析表明,5‘端含有三个被反式作用因子结合的元件,即β蛋白1(BP1)和β蛋白2(BP2)。在体外诱变含有氯霉素乙酰转移酶(PCAT)的β-珠蛋白载体中的每个元件,然后瞬时转染K562细胞,CAT活性水平比wtβ-CAT高5.5倍,这与它们的沉默作用一致。然而,所有这三种元素的突变导致活性显著低于wtβ-CAT。BP1和BP2基序与高迁移率基团蛋白(HMG1+2)有重叠的结合部位,DNA弯曲因子在这里通过循环排列实验显示,以外部弯曲β-珠蛋白远端启动子。从理论上讲,所有β蛋白结合位点的突变都可以影响HMG1+2的结合,从而阻止DNA-蛋白质和/或蛋白质-蛋白质之间的相互作用,这是促进低水平、结构性基因表达所必需的。在BP1和BP2基序之间放置两个螺旋DNA也使表达增加3倍,表明最佳沉默所需的空间限制。然而,插入HMG1+2 DNA弯曲基序(也相当于两个旋转)通过重新建立BP1-BP2邻接关系来促进β沉默。因此,一般DNA弯曲和特定转录因子的组合似乎与胚胎/胎儿红系阶段的β-珠蛋白沉默有关。为了进一步确定这种关系,一项使用转基因动物的体内研究正在进行中。含有突变的BP1沉默基序的uLCRbeta基因的粘粒的制备将允许在体内分析在胚胎/胎儿发育阶段转基因的成人β-珠蛋白基因的表达。我们正在使用两种方法:i)。聚合酶链式反应定点突变和II)。重组-一种限制性内切酶裂解(RARE)方法,用于创建突变的BP1与β-珠蛋白粘粒的结合位点。后一种技术也可能被证明在K562染色体DNA的背景下直接检验这一假设是有用的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GRIFFIN P. RODGERS其他文献

RECOMBINANT ERYTHROPOIETIN IMPROVES THE ANEMIA ASSOCIATED WITH GAUCHER’S DISEASE
  • DOI:
    10.1182/blood.v73.8.2228.2228
  • 发表时间:
    1989-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    GRIFFIN P. RODGERS;LAWRENCE S. LESSIN
  • 通讯作者:
    LAWRENCE S. LESSIN

GRIFFIN P. RODGERS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GRIFFIN P. RODGERS', 18)}}的其他基金

CONTROL OF ERYTHROCYTE HEMOGLOBIN
红细胞血红蛋白的控制
  • 批准号:
    3031311
  • 财政年份:
    1984
  • 资助金额:
    --
  • 项目类别:
REGULATION OF HUMAN DELTA GLOBIN GENE EXPRESSION
人类珠蛋白基因表达的调节
  • 批准号:
    6289738
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
IDENTIFICATION OF GENE EXPRESSION IN POLYCYTHEMIA VERA BY DIFFERENTIAL DISPLAY
通过差异显示鉴定真性红细胞增多症的基因表达
  • 批准号:
    6289741
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Cloning And Characterization Of A Hydroxyurea-inducible
羟基脲诱导剂的克隆和表征
  • 批准号:
    7336241
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
A Liquid Culture System Model for Adult Erythropoiesis at the Molecular Level
分子水平上成人红细胞生成的液体培养系统模型
  • 批准号:
    6105184
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Novel Full-length CDNAs Differentially Expressed During
新型全长 cDNA 在过程中差异表达
  • 批准号:
    7151522
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Cloning/Characterization Of A Hydroxyurea-inducible Gene
羟基脲诱导基因的克隆/表征
  • 批准号:
    7151524
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Effects Of Hydroxyurea On Fetal Hemoglobin Synthesis Bet
羟基脲对胎儿血红蛋白合成的影响
  • 批准号:
    7151520
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
CDNAs Expressed During During Hematopoietic Commitment
造血承诺期间表达的 cDNA
  • 批准号:
    6983694
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
EFFECTS OF HYDROXYUREA ON FETAL HEMOGLOBIN SYNTHESIS BETA-GLOBIN DISORDERS
羟基脲对胎儿血红蛋白合成β-珠蛋白障碍的影响
  • 批准号:
    6289739
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

DNA footprinting of a plant defense gene family; to support visit by A.M. Yorkin, Department of Genetics, St. Petersburg State University, St. Petersburg, Russia
植物防御基因家族的 DNA 足迹;
  • 批准号:
    147394-1992
  • 财政年份:
    1993
  • 资助金额:
    --
  • 项目类别:
    International: Foreign Researcher (H)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了